Assembly Biosciences (FRA:V7B) Net Change in Cash : €-22.72 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Assembly Biosciences's Net Change in Cash for the three months ended in Mar. 2024 was €-1.01 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was €-22.72 Mil.

Assembly Biosciences Net Change in Cash Historical Data

The historical data trend for Assembly Biosciences's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Net Change in Cash Chart

Assembly Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

4.74

10.45

-12.23

6.41

-29.87

Assembly Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															-8.35	-20.18	4.72	-6.25	-1.01

Assembly Biosciences Net Change in Cash Calculation

Assembly Biosciences's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	20.855	+	-63.4	+	12.671	+	0
	=	-29.87

Assembly Biosciences's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -16.895 + 15.89 + 0 + 0

= -1.01

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-22.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Assembly Biosciences's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Assembly Biosciences (FRA:V7B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Net Change in Cash

Comparable Companies

LGVN MTNB SPRB MEIP IMUX DYAI OKYO AGLE TIL BIOR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

ASMB:USA

Address

331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080

Website

https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences (FRA:V7B) Headlines

No Headlines